Anthem Blue Cross Connecticut Commercial Clinical Policy

Anthem Blue Cross Connecticut LAB.00033 Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer Form

Effective Date

04/12/2023

Last Reviewed

02/16/2023

Original Document

  Reference



This document addresses the use of protein biomarkers for the screening, detection and management of prostate cancer, for example: IsoPSA™ (Cleveland Diagnostics, Inc.; Cleveland, OH), 4Kscore test (OPKO Diagnostics, LLC; Woburn, MA), Androgen Receptor Splice Variant-7 (AR-V7), and PanGIA Prostate (Genetics Institute of America; DelRay, FL). This document does not address prostate-specific antigen (PSA) testing.

Note: Please see the following related document(s) for additional information:

  • GENE.00009 Gene Expression Profiling and Genomic Biomarker Tests for Prostate Cancer
  • LAB.00015 Detection of Circulating Tumor Cells

Position Statement

Investigational and Not Medically Necessary:

The use of protein biomarker tests for the screening, detection, and management of prostate cancer is considered investigational and not medically necessary.